The world’s foremost obesity science congress closes in Mexico City today, leaving clinicians, policymakers, and millions of adults who eat packaged food with three findings that reframe how the obesity crisis should be understood — and what to do about it
The first is quantified, consequential, and contested. A modeling study published in the American Journal of Preventive Medicine and formally presented Thursday at the 2026 International Congress on Obesity (ICO 2026) estimates that between 23% and 38% of all cardiovascular deaths in Canada — and 23% to 37% of all new cases of coronary heart disease and stroke — are attributable to consumption of ultra-processed foods (UPFs). Reducing UPF intake by half, the authors calculated, could prevent between 5,000 and 8,300 cardiovascular deaths per year in Canada alone.
The second redefines what GLP-1 receptor agonist drugs — the class behind Ozempic and Wegovy — actually do inside the body. A meta-analysis of ten randomized controlled trials involving more than 23,000 adults without diabetes, presented Wednesday by Dr. Mario Cesar Torres Chavez of Mexico’s National Institute of Cardiology, found that GLP-1 therapy was associated with an approximately 45% reduction in high-sensitivity C-reactive protein (hsCRP), a validated independent predictor of cardiovascular risk. That reduction occurred independent of how much weight participants lost — meaning these medications appear to be fighting cardiovascular disease through a mechanism that has nothing to do with the number on the scale.
The third is a warning about where public attention is headed. Search interest in GLP-1 medications has risen 25-fold since those drugs reached the market, according to a Bar-Ilan University and Stanford University study analyzing Google data from 2016 to 2025. Public interest in lifestyle-based weight loss — diet programs, exercise regimens — has remained essentially flat over the same period. Researchers argue this signals a public health communications crisis: pharmacological solutions are capturing all the attention while the structural food environment that makes obesity nearly inevitable for many people has barely registered on the public radar.
Ultra-Processed Food and Cardiovascular Deaths: What the Numbers Say — and Don’t Say
Dr. Virginie Hamel and Dr. Jean-Claude Moubarac of the University of Montreal Center for Public Health Research led the Canadian modeling study, working from nationally representative 2015 dietary data collected in 2015 and national cardiovascular health statistics from 2019. In that dietary data, ultra-processed foods — NOVA Category 4 items, defined by their use of industrial ingredients and additives largely absent from kitchen cooking — accounted for 43% of Canadian adults’ total daily energy intake.
Applying a comparative risk assessment model to those consumption levels, the team estimated that between 58,200 and 96,000 new cardiovascular disease cases in 2019 were attributable to UPF intake, corresponding to between 235,800 and 388,700 disability-adjusted life-years. The preventable-deaths-from-halving-intake estimate — 5,000 to 8,300 per year — represents the study’s most newsworthy claim, and the authors noted explicitly that similar results would be expected across other high-income countries that share Canada’s dietary patterns.
The study was funded by Heart and Stroke Canada
Independent experts who reviewed the findings through the Science Media Centre’s expert reaction service urged caution before accepting the headline figures at face value. Prof. Gunter Kuhnle of the University of Reading argued that the NOVA classification system, which underpins the entire study, groups an enormous range of foods into a single “harmful” category — treating cola the same as fortified whole-grain cereal — and that the relative risk estimates the model relies on are “based on weak data.” Prof. Tom Sanders of King’s College London noted that cardiovascular deaths in Canada have fallen by roughly 80% over the past two decades — a trend hard to reconcile with the narrative that UPF consumption is a primary cardiovascular killer, given that consumption has not declined in the same period.
Prof. Alberto Fiore of Abertay University went further, arguing that when the UPF-cardiovascular disease signal in the underlying cohort studies is broken down by food subtype, it is “overwhelmingly driven by sugar-sweetened beverages and processed meat products” — foods whose harms have been established for decades on nutritional grounds, without invoking the concept of industrial processing at all. Prof. Kevin McConway of the Open University cautioned that “attributable fraction” is a technical term that does not mean “caused by” — deaths attributed to UPF consumption by this model could also, in a separate model, be attributed to smoking or sedentary behavior, without either model being wrong.
The authors acknowledged several of these limitations in the paper itself, and the range in their own estimates — 5,000 to 8,300 preventable deaths — reflects the uncertainty involved. The scientific direction of the evidence, that diets high in UPFs are associated with worse cardiovascular outcomes, is well-established. Whether “ultra-processing” is a distinct mechanism or a proxy for poor nutritional profiles is a genuinely open question
What the study’s authors consider non-negotiable is the policy implication: “While public education and individual counseling remain important components of health promotion, their impact is limited without broader environmental and policy support,” they wrote. The required structural measures, in their view, are food taxes, front-of-package labeling, marketing restrictions, and reformulation targets
Chile Showed Regulation Works. Canada Has None of It
The starkest contrast at ICO 2026 was between the ambition of the scientific evidence and the reality of food policy in the countries it concerns most. Chile, in a study published in the Lancet in June 2026 and discussed at the congress, provided the first evidence plausibly linking a comprehensive national food policy to measurable reductions in childhood obesity
Chile’s Food Labeling and Advertising Law (FLAL), enacted in 2016, introduced three simultaneous measures: mandatory black-octagon front-of-package warning labels on foods high in sugars, saturated fats, salt, or calories; restrictions on selling those products in schools; and limits on marketing directed at children. Analyzing national data on more than 300,000 schoolchildren aged four to six, researchers found that children who had been at school for 18 months after the law’s introduction were measurably less likely to be overweight or obese than children in the same grades before FLAL. Girls showed a 2.9% reduction in excess weight prevalence; boys, 2.4%.
Canada, whose adults supply the dietary data for the Hamel-Moubarac mortality study, has none of the structural interventions Chile used. The Hamel-Moubarac authors cited Chile’s front-of-package warning system as a proven model, noting that it reduced purchases of high-caloric foods by around a quarter after implementation — and that a 10% sugar-sweetened beverage tax in Mexico led to a 6.3% reduction in UPF consumption
Do GLP-1 Drugs Fight Heart Disease by Fighting Inflammation?
The cardiovascular benefit of GLP-1 receptor agonists has been documented in large randomized trials — most prominently the SELECT trial, which found that weekly semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% in adults with pre-existing cardiovascular disease and obesity but without diabetes. What that trial could not fully explain was why: mediation analyses suggested that only about 33% of the cardiovascular benefit was accounted for by reductions in waist circumference, leaving at least two-thirds of the effect unexplained by weight loss.
The Torres Chavez meta-analysis presented at ICO 2026 offers a candidate mechanism. Across the ten randomized trials and 23,652 participants, GLP-1 receptor agonist therapy was associated with a roughly 45% reduction in hsCRP compared with placebo — a reduction that held even after controlling for the amount of weight lost. High-sensitivity C-reactive protein is not a peripheral marker; it is an independent predictor of cardiovascular events in its own right, validated by large trials including JUPITER. A 45% reduction in hsCRP is, by any clinical standard, a meaningful cardiovascular intervention.
The subgroup findings were specific. Participants with obesity and weight-related cardiometabolic comorbidities showed the greatest hsCRP reduction, at approximately 48%. Those with heart failure with preserved ejection fraction (HFpEF) and those with established cardiovascular disease each showed reductions of approximately 38%. No significant difference in hsCRP reduction was detected between semaglutide and tirzepatide, suggesting the effect is a class property of GLP-1 receptor agonism rather than a quirk of a particular molecule.
This mechanism converges with what the SELECT trial’s prespecified analyses showed: that semaglutide’s cardioprotective benefits appear earlier than weight loss would predict, that they apply regardless of baseline body weight, and that they involve pathways beyond adiposity reduction. The proposed inflammation pathway — GLP-1 receptors expressed on immune cells (macrophages, neutrophils) may directly suppress inflammatory signaling — is consistent with the Torres Chavez findings and the SELECT outcomes, though mechanistic trials to establish the specific contribution of inflammation reduction have not yet been completed.
GLP-1 Search Interest Soared. Lifestyle Interest Stayed Flat
The bar on Ozempic curiosity did not just rise; it changed shape entirely. Prof. Orna Reges of Bar-Ilan University and Dr. Liora Shmueli, also of Bar-Ilan University and a visiting scholar in Stanford University’s Department of Health Policy, analyzed Google search data from 2016 to 2025, tracking how public interest in obesity medication versus lifestyle-based weight management had evolved over a decade
Interest in lifestyle approaches — diet programs, exercise regimens — was consistently high throughout the study period and remained stable across the decade. Interest in obesity medication rose approximately 25-fold and, by 2025, was approaching the level of search volume that lifestyle strategies had long held
“The emergence of these drugs has revolutionized obesity treatment, demonstrating substantial benefit for weight loss and other health outcomes, and has increased public interest in using medication to manage weight,” Prof. Reges said in remarks accompanying the study’s presentation. Dr. Shmueli added the concern that drives the public-health worry: health systems, she argued, need to actively integrate GLP-1 medications with evidence-based lifestyle interventions — and not allow pharmacological enthusiasm to substitute for them.
The search-trend finding dovetails with what Prof. Boyd Swinburn of the University of Auckland argued in the congress’s Public Health track. In a presentation on what he called the “Synergistic Systems Theory,” Swinburn contended that obesity results from the intersection of two systems that are each working exactly as designed: an industrial food system that produces foods engineered to override satiety signaling before fullness is reached, and a human energy-balance system that is evolutionarily biased toward weight gain. Neither system is malfunctioning. That is precisely the problem.
If that framing is correct, the 25-fold growth in interest in GLP-1 drugs is itself a symptom: the tools that address the symptom (excess weight) are attracting all the public attention, while the systems that produce the symptom (the food environment, the food industry’s design choices) remain largely outside the frame of popular discourse
Read more:GLP-1 Drugs 2026: ADA Sessions Close as New Standards End Single-Goal Diabetes Care
Do GLP-1 Drugs Eliminate the Need for Bariatric Surgery?
The question that IFSO — the International Federation for the Surgery of Obesity and Metabolic Disorders — brought to Friday’s symposium was not defensive. Bariatric surgery programs worldwide are actively recalibrating rather than retreating in the face of pharmacotherapy
Surgeons at the symposium presented evidence that metabolic bariatric surgery retains distinct advantages for specific patient subgroups: those with severe obesity, those who respond inadequately to pharmacotherapy, and those whose obesity-related comorbidities — type 2 diabetes in particular — benefit from the additional metabolic effects of surgical anatomy changes. Both bariatric surgery and GLP-1 receptor agonists can achieve substantial and sustained weight loss in many patients. What they do not do is the same thing through the same mechanism, and the evidence presented at the symposium suggested that patient selection and sequencing — rather than competition — is the clinically productive frame.
The symposium’s framing of “multimodal obesity care” — combining surgical, pharmacological, lifestyle, and emerging precision approaches — is the structural conclusion of the entire congress: no single modality, the ICO 2026 science makes plain, addresses the full complexity of obesity for every patient across a lifetime
Can Measuring Food Environments Accelerate Policy Change?
A recurring theme at ICO 2026 was the gap between what the science shows can reduce obesity and what governments have actually implemented. INFORMAS — the International Network for Food and Obesity/Non-Communicable Diseases Research, Monitoring and Action Support — presented updated tools for benchmarking national food environments in Friday’s Public Health session
The INFORMAS framework tracks the availability, affordability, and promotion of healthy and unhealthy foods as a policy input — providing the kind of standardized cross-country comparisons that can hold governments accountable for their food environments. The WHO-UNICEF Acceleration Plan session on Thursday reviewed progress toward the 2026 Madrid Global Stocktaking and the 2030 obesity targets established under the plan
The ICO 2026 closing ceremony this afternoon includes the presentation of the Philip James Award and the announcement of the host city for ICO 2028. The event is the first International Congress on Obesity to have been held in Latin America in the congress’s five-decade history — a geographic signal that a federation led by Dr. Simón Barquera, president of the World Obesity Federation and director of the Centre for Research in Nutrition and Health at Mexico’s National Institute of Public Health, chose deliberately, given the region’s acute burden of obesity-driven non-communicable disease.
What ICO 2026 Leaves on the Table
Three days of science in Mexico City produced a coherent picture that is less comfortable than either the pharmaceutical industry or the food industry would prefer it to be
Ultra-processed foods impose a measurable and potentially large cardiovascular burden — but the specific size of that burden remains statistically contested, and the policy tools to reduce it (front-of-package labels, marketing restrictions, food taxes) are proven in Chile but absent in many of the countries the Canadian study implies most need them
GLP-1 receptor agonists are not just weight-loss drugs. They appear to fight cardiovascular disease through an anti-inflammatory mechanism independent of weight loss — making them, in the Torres Chavez framing, a class of cardiovascular medicines that happen to produce weight loss as a secondary effect, rather than the reverse. That reframing has prescribing, coverage, and health-equity implications that the SELECT trial and ICO 2026 together make hard to ignore
And the 25-fold surge in GLP-1 search interest, against a flat baseline of lifestyle-strategy interest, is a public health communications problem that has no pharmacological solution: the tools that are easiest to market will attract the most attention, regardless of whether the structural drivers of the disease they treat are being addressed
Frequently Asked Questions
Can reducing ultra-processed food intake genuinely prevent thousands of heart disease deaths?
A 2026 modeling study from the University of Montreal estimated that halving ultra-processed food consumption could prevent between 5,000 and 8,300 cardiovascular deaths per year in Canada, based on the finding that UPF consumption appears to account for 23–38% of all cardiovascular deaths in that country. However, multiple independent experts have pointed out that the model relies on observational risk estimates that may overstate the causal effect, that attributable fraction statistics can double-count across multiple risk factors like smoking and socioeconomic disadvantage, and that the risk estimates were drawn from studies in France, Italy, and the United States — not Canada. The direction of the evidence is consistent: high-UPF diets are associated with worse cardiovascular outcomes. The specific death-toll figures should be understood as estimates with significant uncertainty, not confirmed causal projections.
Does semaglutide (Ozempic/Wegovy) reduce heart disease risk by something other than weight loss?
Yes — that is what the Torres Chavez meta-analysis presented at ICO 2026 found, and what pre-specified analyses of the SELECT trial also suggested. Across ten randomized controlled trials involving more than 23,000 adults without diabetes, GLP-1 receptor agonist therapy was associated with an approximately 45% reduction in high-sensitivity C-reactive protein (hsCRP), a validated independent predictor of cardiovascular events, even after accounting for weight lost. In the SELECT trial, only about a third of semaglutide’s cardiovascular benefit could be attributed to reductions in waist circumference. The proposed mechanism involves direct anti-inflammatory effects of GLP-1 receptor activation on immune cells — though mechanistic trials to confirm this pathway are still under way.
Is bariatric surgery still worth considering if GLP-1 drugs are available?
Evidence presented at ICO 2026’s IFSO symposium on Friday suggested that for specific patient groups — those with severe obesity, those who do not respond adequately to pharmacotherapy, and those with obesity-related conditions like type 2 diabetes that benefit from the metabolic effects of surgical anatomy changes — bariatric surgery continues to offer distinct advantages over GLP-1 medications alone. The emerging clinical consensus is not “surgery or drugs” but rather sequential or complementary use of both within what the field calls multimodal obesity care. A patient’s specific health profile, comorbidities, and response to pharmacotherapy all inform which modality is appropriate.
Should people in high-UPF countries be reducing their intake even without a front-of-pack warning label?
The science says yes. The mechanistic logic for reducing ultra-processed food intake — particularly sugar-sweetened beverages and processed meat products, which show the strongest cardiovascular signals — is established independently of whether governments have implemented food-labeling laws. The ICO 2026 Chile evidence suggests that structural policy helps reduce UPF consumption at a population level, but the absence of such policy in a given country does not change the individual dietary evidence. Adults can meaningfully reduce cardiovascular risk through dietary shifts toward whole or minimally processed foods, regardless of whether their government has mandated octagon labels. Clinicians can use the quantified burden evidence from this study — even with its stated caveats — to motivate dietary counseling conversations.
ⓒ 2026 TECHTIMES.com All rights reserved. Do not reproduce without permission
Tags:Heart DiseaseObesityOzempicPublic health
